DiaMedica Therapeutics Inc. (DMAC) Quick Ratio
- Quick ratio · latest quarter: Value 6.63×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 6.63× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $43.75M ÷ $6.59M ≈ 6.63× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 43.75M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 6.59M USD | Liabilities, Current |
| Cash and equivalents | 5.13M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 38.38M USD | Marketable Securities, Current |
| Customer receivables | 244.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.75M | $6.59M | $5.13M | $38.38M | $244.00K | (m) | 6.63× |
| 2026-03-31 | $51.63M | $5.75M | $4.87M | $46.46M | $301.00K | (m) | 8.98× |
| 2025-12-31 | $60.15M | $5.13M | $15.65M | $44.24M | $258.00K | (m) | 11.72× |
| 2025-09-30 | $55.58M | $5.27M | $3.33M | $51.99M | $260.00K | (m) | 10.55× |
| 2025-06-30 | $30.20M | $4.12M | $4.11M | $25.93M | $161.00K | (m) | 7.34× |
| 2025-03-31 | $36.57M | $4.67M | $2.59M | $33.73M | $253.00K | (m) | 7.84× |
| 2024-12-31 | $44.38M | $5.39M | $3.02M | $41.12M | $236.00K | (m) | 8.23× |
| 2024-09-30 | $50.49M | $4.30M | $4.13M | $46.06M | $290.00K | (m) | 11.75× |
| 2024-06-30 | $54.45M | $3.09M | $14.07M | $39.99M | $391.00K | (m) | 17.63× |
| 2024-03-31 | $46.91M | $2.62M | $2.10M | $44.42M | $399.00K | (m) | 17.93× |
| 2023-12-31 | $53.26M | $2.79M | $4.54M | $48.35M | $369.00K | (m) | 19.12× |
| 2023-09-30 | $46.77M | $2.17M | $2.23M | $44.23M | $310.00K | (m) | 21.56× |
| 2023-06-30 | $40.56M | $1.95M | $5.84M | $34.53M | $188.00K | (m) | 20.84× |
| 2023-03-31 | $28.71M | $2.81M | $2.15M | $26.51M | $57.00K | (m) | 10.20× |
| 2022-12-31 | $33.58M | $2.17M | $4.73M | $28.77M | $82.00K | (m) | 15.49× |
| 2022-09-30 | $36.16M | $1.54M | $2.77M | $33.31M | $75.00K | (m) | 23.45× |
| 2022-06-30 | $38.53M | $1.54M | $3.06M | $35.38M | $88.00K | (m) | 25.09× |
| 2022-03-31 | $41.22M | $1.43M | $3.03M | $38.02M | $168.00K | (m) | 28.74× |
| 2021-12-31 | $45.24M | $1.52M | $4.71M | $40.41M | $130.00K | (m) | 29.69× |
| 2021-09-30 | $48.20M | $1.62M | $16.22M | $31.88M | $104.00K | (m) | 29.68× |
| 2021-06-30 | $21.31M | $1.44M | $2.23M | $19.07M | $16.00K | (m) | 14.80× |
| 2021-03-31 | $23.74M | $1.18M | $3.33M | $20.07M | $337.00K | (m) | 20.15× |
| 2020-12-31 | $27.85M | $2.03M | $7.41M | $20.10M | $340.00K | (m) | 13.73× |
| 2020-09-30 | $30.96M | $1.44M | $9.80M | $20.83M | $335.00K | (m) | 21.45× |
| 2020-06-30 | $12.12M | $1.22M | $4.96M | $6.84M | $319.00K | (m) | 9.96× |
| 2020-03-31 | $13.63M | $935.00K | $3.30M | $9.35M | $985.00K | (m) | 14.58× |
| 2019-12-31 | $8.70M | $1.32M | $3.88M | $4.00M | $823.00K | (m) | 6.60× |
| 2019-09-30 | $10.41M | $1.21M | $4.74M | $5.00M | $664.00K | (m) | 8.64× |
| 2019-06-30 | $12.08M | $947.00K | $2.97M | $7.99M | $1.11M | (m) | 12.75× |
| 2019-03-31 | $14.65M | $1.43M | $2.76M | $10.96M | $929.00K | (m) | 10.28× |
| 2018-12-31 | (m) | $1.30M | (m) | (m) | $780.00K | (m) | (m) |
| 2018-09-30 | (m) | (m) | $3.90M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $5.73M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $6.71M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $1.00M | (m) | (m) | $80.00K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |